Catabasis Pharmaceuticals, Inc. Invited To Present In A Webinar Hosted By Parent Project Muscular Dystrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that Joanne Donovan, M.D., Ph.D., chief medical officer of Catabasis, has been invited by Parent Project Muscular Dystrophy (PPMD) to present on the Company’s upcoming MoveDMD trial. MoveDMD is a Phase 1 / 2 clinical trial of CAT-1004 for the treatment of boys with Duchenne muscular dystrophy (DMD) regardless of dystrophin mutation. The presentation will take place on Wednesday, May 13, from 1pm to 2pm ET. The webinar is intended for parents of boys with DMD to describe the MoveDMD trial design and provide enrollment guidance.

Help employers find you! Check out all the jobs and post your resume.